Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Aug
13
Today In Oncology
Global Survey Identifies Barriers to Integrative Oncology Use in Cancer Care
AI Biomarker May Guide Adjuvant Chemotherapy in Resected Pancreatic Cancer
First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer
NIH-Funded International Research Yields Patient-Derived Tumor Compendium
Stanford Appoints New Leader to Expand Impact in Early Drug Development
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo